LGALS1 and melanoma: Gal‐1 genetic inhibition with antisense oligonucleotides in a B16 murine melanoma model led to immune‐mediated rejection of the tumor (Rubinstein et al., 2004), suggesting that its expression in melanoma cells is an important mediator of tumor immune privilege.